ICD vs DSM-Firmenich Which Is a Smarter Choice?

ICD and DSM-Firmenich are two multinational corporations that operate in different industries - ICD is a global supplier of specialized metal parts and components, while DSM-Firmenich is a leader in the fragrance and flavor industry. Despite their differences, both companies are publicly traded on the stock market and have garnered significant investor interest. In this analysis, we will compare and contrast the stock performance of ICD and DSM-Firmenich, examining key financial metrics and market trends to determine which company may offer the most promising investment opportunity.

ICD or DSM-Firmenich?

When comparing ICD and DSM-Firmenich, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between ICD and DSM-Firmenich.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. ICD has a dividend yield of 2.17%, while DSM-Firmenich has a dividend yield of 2.37%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. ICD reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%. On the other hand, DSM-Firmenich reports a 5-year dividend growth of 0.00% year and a payout ratio of -426.58%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with ICD P/E ratio at -2.33 and DSM-Firmenich's P/E ratio at -146.94. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. ICD P/B ratio is 0.62 while DSM-Firmenich's P/B ratio is 1.26.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, ICD has seen a 5-year revenue growth of -0.73%, while DSM-Firmenich's is -0.13%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with ICD's ROE at -24.46% and DSM-Firmenich's ROE at -0.84%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are ₩4500.00 for ICD and €105.10 for DSM-Firmenich. Over the past year, ICD's prices ranged from ₩4475.00 to ₩11580.00, with a yearly change of 158.77%. DSM-Firmenich's prices fluctuated between €83.55 and €124.85, with a yearly change of 49.43%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.